Similar articles

• Methods for determining cost-benefit ratios for pharmaceuticals in Germany.

  von der Schulenburg J, Vauth C, Mittendorf T, Greiner W. von der Schulenburg J, et al. Eur J Health Econ. 2007 Sep;8 Suppl 1:S5-31. doi: 10.1007/s10198-007-0063-4. Eur J Health Econ. 2007. PMID: 17582539 Review.
• Technology assessment in the German context.

  Drummond M. Drummond M. Eur J Health Econ. 2007 Sep;8 Suppl 1:S3. doi: 10.1007/s10198-007-0067-0. Eur J Health Econ. 2007. PMID: 17619919 No abstract available.
• Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.

  Chaps NA. Chaps NA. Issue Brief Health Policy Track Serv. 2008 Jan 7:1-23. Issue Brief Health Policy Track Serv. 2008. PMID: 18345558 No abstract available.
• Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.

  Chaps NA. Chaps NA. Issue Brief Health Policy Track Serv. 2009 Jan 5:1-26. Issue Brief Health Policy Track Serv. 2009. PMID: 19301435 No abstract available.
• [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].

  Castillo-Laborde C, Silva-Illanes N. Castillo-Laborde C, et al. Rev Med Chil. 2014 Jan;142 Suppl 1:S33-8. doi: 10.4067/S0034-98872014001300006. Rev Med Chil. 2014. PMID: 24861178 Review. Spanish.